🥁#ESMO25 ABSTRACT RELEASE DAY🥁 #ESMO25 is shaping up to be one of most impactful conferences in recent memory with #PracticeChangingData in Prostate, Bladder and Kidney Cancers! 💫See list of highlighted abstracts 👇

⚡️ Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study #BladderCancer https://t.co/L2tJHr0xEt

🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 https://t.co/BYx1L9i7GC @PCFnews @OncoAlert @urotoday

@Ecastromarcos Proud and super happy to have you in Toulouse, thanks President 🎉🇪🇸 @GPloussard @RoubaudG @FocusMeeting @MRoupret @delataillealex @fcounago @CZamboglou

@FocusMeeting it’s tomorrow at the Pierre Baudis Convention Center #Toulouse ! With our presidents @Ecastromarcos et @kbensalah35🇪🇸🇫🇷 #focus2025meetsSpain #urology #oncology #radiotherapy @jbbeauval @PignotG @GPloussard @PouesselD @RoubaudG @MRoumiguie @PaulSargos

This is bad news. This is very bad news. The US government has stopped the funding of PubMed, the most comprehensive database of biomedical literature. Why would you do this? This database it literally a matter of life and death.

Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study https://t.co/1zQ36d5KL4 This study evaluated how well Transurethral Resection of Bladder Tumor (TURBT)

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial https://t.co/OuecAjtuGm This post-hoc analysis of the phase III PEACE-1 trial examined the impact of post-progression abiraterone

@FocusMeeting change de lieu en 2025 : nous vous attendons au Centre de congrès Pierre Baudis à #Toulouse ! 🗓 9 et 10 octobre 2025 💻 Inscriptions/Demande de prise en charge : https://t.co/VRfnge7VYX @jbbeauval @PignotG @GPloussard @PouesselD @RoubaudG @MRoumiguie @PaulSargos

✍️ Editorial in European Urology: In the PROBASE trial, 26% of significant prostate cancers in men 45–50 would have been missed with MRI-targeted biopsy alone. 👉 Stabile & Nordström argue systematic biopsy remains essential for young men. 🔗 https://t.co/FS02DWTQQz

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9) https://t.co/4Q4if9OBrC The phase 2 PCS-9 trial evaluated the addition of stereotactic body radiotherapy (SBRT) to standard

In this short case-based discussion, @Achard_Verane discusses the management of a patient with postoperative PCa recurrence 👉 Check out the video via this link: https://t.co/31oQnuNSnj @OncoAlert

✨ 🔥🔥New Editorial in @EUplatinum EMBARK puts ARPIs in the spotlight, but where does RT stand in high-risk BCR? 💡 Perspectives, open questions, insights on imaging, MDT & integration 🚀 #radoncGUcommunity #PCa https://t.co/VRwF2mXrpj

As an oncologist & researcher, I truly value the importance of targeting TP53. Interim phase 1/2 data of Rezatapopt (PC14586) in TP53 Y220C–mutated tumors: ☑️ORR 33% overall, 43% in ovarian cancer ☑️mDOR 6.2 mo. This could be a turning point for resistant cancers.

Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? "Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. " An

PRIME trial: Biparametric MRI (no contrast) caught significant prostate cancer as well as full multiparametric scans. Shorter, cheaper, safer, could reset the standard of care worldwide? #ProstateCancer #Oncology doi:10.1001/jama.2025.13722 @JAMA_current @APCCC_Lugano @PCFnews

⚡Guidelines Alert: 🔗Management of testis cancer for #radoncs ✨Out now 👏 @CharlesRaynaud @PBlanchardMD @JennKa12 @stephanesupiot @maximilienroge @RoubaudG @SFjROfr https://t.co/JB9HnKLHaS

FDA just approved intravesical gemcitabine system for BCG-unresponsive NMIBC with CIS ± papillary tumors. CR rate 82%, half lasting ≥12 months. A new door for patients. @US_FDA @OncoAlert @WorldBladderCan @FDA

Another proof that metastasis directed therapy improves outcomes, this time in castration resistant #prostatecancer Congrats to the PCS IX team! author link at @TheLancetOncol: https://t.co/SLt68cCuQP

Really exciting proof-of-concept data that intravesical drug release plus IO can lead to pCR: numerically even higher than NIAGARA! The pretzel device can have a major impact on future NMIBC & MIBC therapy! Congrats to @AndreaNecchi et al @TheLancetOncol @urotoday